Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), persists within infected macrophages for long periods of time in a metabolically inactive but reversible state known as dormancy. Since the majority of adult pulmonary TB is caused by the reactivation of persistent Mtb, novel vaccines to protect against disease reactivation and novel biomarkers to provide the basis of new diagnosis of latent infection are urgently needed. To meet this demand, we assessed the immunogenicity of 32 latency-associated proteins in DNA-vaccinated mice. By using a Helios gene gun, BALB/c and C57BL/6 mice were vaccinated with plasmids carrying DNAs for latency-associated antigens encoded by the DosR regulon. Of the 32 antigens tested, 12 induced antigen-specific T-cell responses in vaccinated BALB/c mice and 9 induced responses in C57BL/6 mice. Five antigens (Rv1998c, Rv2031c, Rv2032, Rv2623, and Rv3132c) induced T-cell responses in both mice strains. In addition, at least 12 and 3 antigens induced antigen-specific antibody production in vaccinated BALB/c and C57BL/6 mice, respectively. Of these, 3 antigens (Rv2029c, Rv2626c, and Rv3132c) induced strong antibody production in both mice strains. These results might be applicable for the future development of a novel vaccine and biomarkers for latent TB infection, although further analyses in human blood samples are necessary.
Introduction
Tuberculosis (TB) has plagued humans for thousands of years, and more than 2 billion people (equal to approximately one-third of the world's population) are currently infected with the causative agent Mycobacterium tuberculosis (Mtb) (1) . However, less than 10% of the infected individuals actually develop active diseases (approximately 9.4 million new incidences in 2008) (1) , and Mtb infection remains latent with no overt clinical symptoms throughout the life in more than 90% of infected individuals. Such statistical evidence indicates the efficacy of naturally induced immune responses, at least in the resistant population. The risk of developing active TB is increased in immunocompromised individuals, especially in HIV-positive people (1) . While infected immunocompetent individuals mount a cell-mediated immune response against Mtb, most of them do not achieve complete eradication of the microbe (2 5) . Consequently, Mtb bacilli can persist within the human body, especially in the lung, for long periods of time in a metabolically inactive but reversible state known as dormancy (2 5) . The major cause of adult pulmonary TB, the most prevalent form of the disease, is reactivation of such persistent Mtb bacilli (6) , although the differences between resistant and susceptible populations to TB reactivation are not fully understood.
The current TB vaccine Mycobacterium bovis Bacillus Calmette-Guérin (BCG) was developed nearly 90 years ago and is the most widely used vaccine worldwide (7 10), although it has been reported to exhibit variable protective efficacy (11) . This vaccine efficiently protects against severe disseminated TB (miliary TB) in newborns and young children, but fails to prevent adult pulmonary TB. Accordingly, BCG has virtually no effect on TB transmission in the adult population (12) . The ineffectiveness of BCG to protect against the highly prevalent TB in adults has stimulated many efforts to establish more effective vaccine protocols. In general, these attempts can be divided into two categories, i.e., (i) subunit vaccines composed of one or a few antigens and (ii) recombinant viable vaccines superior to BCG (7, 8) . Considering the complementary strength of both types of vaccines, a heterologous prime-boost regimen comprising a prime with a viable vaccine superior to BCG and a boost with a subunit vaccine seems to be the most promising combination (7, 8) .
After Mtb enters the lungs by inhalation, the bacterial cell is engulfed by alveolar macrophages and probably dendritic cells (DCs); however, Mtb can escape from digestion by these phagocytic cells (13) . Consequently, infected macrophages and DCs serve as mobile reservoirs that transport the bacteria, eventually to draining lymph nodes, where presentation of mycobacterial antigens to T cells occurs (2 5). As a regional immune response, activated antigen-specific T cells induce the formation of a granuloma around infected macrophages, primarily composed of monocyte-derived macrophages, CD4 + T cells, and CD8 + T cells (14) . In the granuloma, surrounding T cells activate macrophages through the production of Th1 cytokines such as interferon (IFN)-and tumor necrosis factor (TNF)- (14) , and IFN-augments the capacity to control Mtb in macrophages (15, 16) . The granuloma can persist for years and deprive the arrested Mtb of oxygen and nutrients; therefore, the bacterial cells survive probably in a state of dormancy (17) (18) (19) (20) . Recent DNA microarray analysis revealed upregulation of the DosR regulon, which comprises 48 genes (including the heat shock protein (hsp) X/ -crystallin), in Mtb during its dormancy state (19, 20) . Therefore, in this study, we assessed the immunogenicity of these antigens in DNA-vaccinated mice. We anticipate that our results can provide useful information not only for the establishment of novel vaccines to control TB reactivation but also for the development of biomarkers for new diagnosis of latent Mtb infection.
Materials and Methods

Preparation of DNAs
DNAs encoding the DosR regulon proteins (20) were amplified by PCR using genomic DNAs of Mtb H37Rv or BCG as templates. Primers were designed according to the genetic information obtained from the TubercuList (http://genolist.pasteur.fr/TubercuList/). Appropriate restriction sites were introduced at the 5 and 3 ends of the DNAs by PCR, and the PCR products were digested and ligated into the corresponding restriction sites of pCI (Promega, Madison, WI, USA) and pET-28b(+) (Novagen/Merck, Darmstadt, Germany) vectors for DNA vaccine and recombinant protein preparation, respectively. Plasmids were purified using commercially available Plasmid Purification Kits (Qiagen GmbH, Hilden, Germany), according to the manufacturer's instructions. The nucleotide sequences were confirmed by automated DNA sequencing (ABI PRISM 310 Genetic Analyzer, Applied Biosystems, Foster City, CA, USA) using a dye primer cycle sequencing kit (Applied Biosystems).
Preparation of recombinant proteins
Escherichia coli BL21(DE3) competent cells (Novagen/Merck) were transformed with pET-28(+) vectors containing the DNAs for the DosR regulon proteins. Proteins were induced with isopropyl -D(-)-thiogalactopyranoside (IPTG, Wako Pure Chemical Industries, Ltd., Osaka, Japan). Proteins were extracted from the bacterial cells with 7 M urea (Wako Pure Chemical Industries, Ltd.) and purified by Ni 2+ -nitrilotriacetic acid (Ni-NTA) agarose (Qiagen) according to the manufacturer's instructions.
Mice and vaccination
Female BALB/c and C57BL/6 mice (8 and 12 weeks of age) were purchased from Japan SLC (Hamamatsu, Japan) and maintained in the animal facility of Hamamatsu University School of Medicine under specific pathogenfree conditions. All animal experiments were performed according to the Guidelines for Animal Experimentation issued by the Hamamatsu University School of Medicine. Mice were vaccinated with plasmids using a Helios gene gun system (Bio-Rad Laboratories, Hercules, CA, USA) three times at 2-week intervals as described previously (21).
Enzyme-linked immunosorbent assay (ELISA) for IFN-
Two weeks after the last vaccination, spleen cells from the vaccinated and non-vaccinated control mice were cultured in a 96-well plate (1 × 10 6 cells/0.2 ml/well) in the presence or absence of corresponding antigens for 2 days. IFN-concentration of the culture supernatants was determined by a sandwich ELISA as described previously (21).
Serum preparation and antibody titration
Two weeks after the last vaccination, sera from the vaccinated mice were prepared as described (22) . Prevaccinated sera from the corresponding vaccinated mice were also prepared. Indirect ELISA to detect antigenspecific antibodies in the sera from mice (both pre-and post-vaccination) was conducted as described (23), with slight modifications, using peroxidase-labeled goat anti-mouse IgG+A+M (H+L) antibody (Zymed/Invitrogen, Carlsbad, CA, USA) and 3,3 ,5,5 -tetramethylbenzidine (TMB) (BioFX Laboratories, Owings Mills, MD, USA). Fig. 1 . Experimental design for the measurement of T-cell responses against latency-associated antigens. DNAs for DosR regulon proteins were obtained by PCR using the genomic DNA of Mtb H37Rv or BCG as templates and were cloned into pCI and pET-28b(+) vectors for DNA vaccine and recombinant protein preparation, respectively. By using a Helios gene gun, BALB/c and C57BL/6 mice were vaccinated three times at 2-week intervals with the plasmids encoding antigen DNA. Two weeks after the last vaccination, spleen cells from the vaccinated and nonvaccinated mice were stimulated with corresponding antigen proteins prepared by the bacterial pET system, and the production of IFN-was tested by ELISA.
Results and Discussion
T cell responses against DosR regulon-encoded antigens were measured as illustrated in Fig. 1 . The results of these experiments are shown in Fig. 2 and Table 1 . Of the 32 DosR regulon-encoded antigens tested, 12 induced antigen-specific T-cell responses in vaccinated BALB/c mice and 9 induced responses in C57BL/6 mice. Of these antigens that induced responses, 5 antigens (Rv1998c, Rv2031c, Rv2032, Rv2623, and Rv3132c) induced T-cell responses in both mice strains, although the intensity of their responses varied. The antigen Rv0079 also showed a strong immunogenicity in a single BALB/c mouse and in 2 C57BL/6 mice, but failed to induce a T-cell response in the BALB/c mouse. In addition, Rv2628 induced strong T-cell responses in BALB/c mice only. In contrast, Rv2624c induced intermediate T-cell responses in C57BL/6 mice, while its immunogenicity was relatively low in BALB/c mice. Antibody production against DosR regulon-encoded antigens in DNA-vaccinated mice was also examined, although some results have yet to be obtained. As shown in Fig. 3 and Table 1 , at least 12 DosR regulon-encoded antigens induced antigen-specific antibody production in vaccinated BALB/c and 3 antigens induced antibody production in C57BL/6 mice. Of the antigens that produced antibody, 3 antigens (Rv2029c, Rv2626c, and Rv3132c) induced strong antibody production in both mice strains (Figs. 3 and 4 ). Rv0081 and Rv2624c also induced strong antibody production in BALB/c mice, while their effects in C57BL/6 mice have not been tested. Table 1 summarizes the present study results and shows the results of a previous report for comparison (24) . Both studies showed that Rv2031c (hsp X/ -crystallin) effectively induced antigen-specific cellular and humoral immune responses in both mice strains, although we have not assessed the humoral response in C57BL/6 mice. In addition to Rv2031c, our present study also showed that Rv3132c (desV) induced antigen-specific cellular and humoral immune responses in both mice strains, although its immunogenicity in T-cell responses seemed relatively low.
Rv2032 also showed a similar immunogenicity between the two studies, i.e., only T-cell responses were induced in both BALB/c and C57BL/6 mice. On the other hand, while Roupie et al. showed high and intermediate IFNproduction by spleen cells from vaccinated C57BL/6 mice in response to Rv2626c and Rv2628, respectively, we did not detect T-cell responses against these antigens in the same strain. The discordance may stem from the differences in DNA-vaccine constructs, vaccination formula, and/or assay conditions, but the actual cause(s) has not been clarified. Some differences were also observed across studies in the results for the antigens showing low immunogenicity.
IFN--secreting CD4 + T cells, also known as Th1 cells, are important mediators of TB protection (15, 16) . Attempts to induce TB antigen-specific Th1 cells have been the dominant theme of most TB vaccine development studies (7, 8) . In addition, accumulating evidence shows that CD8 + cytotoxic T lymphocytes (CTLs) also contribute to disease resistance (2 5) . Therefore, identification of highly immunogenic antigens recognized by T cells is a particularly important step in the development of TB vaccines. However, since T-cell responses are induced in an MHC-restricted manner (25, 26) , T-cell antigens found in murine systems are not necessarily applicable for human vaccines. In addition, HLA heterogeneity should also be considered during vaccine development. Recent studies revealed that the immunogenicity of latency-associated antigens varies not only between individuals of European and African descent but also among African people (27, 28) . MHC class II binding motifs, however, are not as tightly restricted as those of MHC class I (29) . Promiscuous peptides binding to different MHC class II molecules have been reported (30) . Of note, some promiscuous peptides are associated with both mouse and human MHC class II molecules (31, 32) . We are currently attempting to identify T-cell epitopes on the antigens found immunogenic in this study that are shared by both mouse and human MHC class II molecules.
In addition to the establishment of vaccine protocols and therapeutic regimens against TB, another important issue in TB management is the development of biomarkers applicable for monitoring clinical trials and for making more rapid and accurate diagnoses and prognoses of the outcome of infections and drug treatments (33, 34) . For TB diagnosis, a tuberculin skin test (TST) is still used today, although this test has many major disadvantages, including poor specificity (false-positive tests caused by prior vaccination or previous exposure to environmental mycobacteria) and poor sensitivity (false-negative tests in children and immunocompromised individuals) (34) . Newly established IFN-release assays using specific antigens of ESAT-6 and CFP-10, such as the QuantiFERON-TB Gold test (Cellestis Limited, Carnegie, Victoria, Australia) and the T-SPOT.TB test (Oxford Immunotech Limited, Abingdon, UK), can differentiate infection from BCG vaccination, but these methods still have some limitations (35) .
We are hopeful that the immune responses against latency-associated antigens observed in this study can ultimately be used as biomarkers for the diagnosis of latent infection of Mtb. To this end, we have initiated a few human studies to measure the immunogenicity of latency-associated antigens. Since antibody-based assays are generally easier and cheaper than T cell-based assays, the former may be particularly suitable for the measurement of biomarkers, especially in developing countries. In this regard, we have found 3 strong B-cell antigens (Rv2029c, Rv2626c, and Rv3132c) that are commonly immunogenic in both strains tested. Rv0079, Rv0080, Rv1738, Rv2626c, and Rv3127 potentially have similar characteristics. Therefore, it would be interesting to verify whether the antibody production against these antigens in humans can be used as the biomarkers for the diagnosis of latent infections and/or active diseases. Such a study is currently in progress.
In conclusion, in this study we assessed the immunogenicity of latency-associated antigens in DNA-vaccinated mice and found that of 32 antigens, 12 and 9 antigens induced antigen-specific T-cell responses in vaccinated BALB/c and C57BL/6 mice, respectively. In addition, we found that at least 12 antigens induced antigen-specific antibody production in vaccinated BALB/c and 3 induced production in C57BL/6 mice. Our next aims are to identify the epitopes on these T-cell antigens and to assess the immune responses against them by using human blood samples. from the Ministry of Health, Labour and Welfare of Japan; and the United States-Japan Cooperative Medical Science Committee.
